Proposals for Revised IWG 2018 Hematological Response Criteria in Patients with MDS Included in Clinical Trials

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2018 Nov 9

PMID 30404811

Citations 53

Authors

U Platzbecker

P Fenaux

L Ades

A Giagounidis

V Santini

A A van de Loosdrecht

D Bowen

T de Witte

G Garcia-Manero

E Hellstrom-Lindberg

U Germing

R Stauder

L Malcovati

Mikkael A Sekeres

David P Steensma

S Gloaguen

Affiliations

Soon will be listed here.

Abstract

The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group (IWG) proposed a revision to previously published standardized response criteria (IWG 2000) for uniformly evaluating clinical responses in MDSs. These IWG 2006 criteria have been used prospectively in many clinical trials in MDSs, but proved challenging in several of them, especially for the evaluation of erythroid response. In this report, we provide rationale for modifications (IWG 2018) of these recommendations, mainly for "hematological improvement" criteria used for lower-risk MDSs, based on recent practical and reported experience in clinical trials. Most suggestions relate to erythroid response assessment, which are refined in an overall more stringent manner. Two major proposed changes are the differentiation between "procedures" and "criteria" for hematologic improvement-erythroid assessment and a new categorization of transfusion-burden subgroups.

Citing Articles

Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion.

Chang Y, Liu L, Cui C, He J, Li C, Jia Y Cancer Med. 2025; 14(5):e70747.

PMID: 40047093 PMC: 11883421. DOI: 10.1002/cam4.70747.

Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases.

Kunimoto H, Sakuma T, Ohashi T, Shirafuta M, Teranaka H, Nakajima H EJHaem. 2024; 5(6):1335-1339.

PMID: 39691241 PMC: 11647689. DOI: 10.1002/jha2.1057.

A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.

Haque T, Shastri A, Desai P, Xie Z, Hammond D, King Z Br J Haematol. 2024; 206(2):416-427.

PMID: 39653653 PMC: 11829135. DOI: 10.1111/bjh.19925.

Preoperative anemia is associated with increased length of stay in adult spinal deformity surgery: evaluation of a large single-center patient cohort and future suggestions for patient optimization.

Dagli M, Wathen C, Golubovsky J, Ghenbot Y, Arena J, Santangelo G Spine Deform. 2024; 13(2):625-637.

PMID: 39509012 PMC: 11893697. DOI: 10.1007/s43390-024-01003-w.

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.

Jacoby M, Duncavage E, Khanna A, Chang G, Nonavinkere Srivatsan S, Miller C Leukemia. 2024; 39(1):166-177.

PMID: 39367170 DOI: 10.1038/s41375-024-02426-0.

References

Alessandrino E, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato L . Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87(12):1286-306. View

Dharmarajan T, Pankratov A, Morris E, Qurashi S, Law G, Phillips S . Anemia: its impact on hospitalizations and length of hospital stay in nursing home and community older adults. J Am Med Dir Assoc. 2008; 9(5):354-9. DOI: 10.1016/j.jamda.2008.02.008. View

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, cermak J, Del Canizo C . Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-64. PMC: 3811170. DOI: 10.1182/blood-2013-03-492884. View

Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N . Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016; 34(25):2988-96. DOI: 10.1200/JCO.2015.66.0118. View

Steensma D, Heptinstall K, Johnson V, Novotny P, Sloan J, Camoriano J . Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2007; 32(5):691-8. DOI: 10.1016/j.leukres.2007.10.015. View

Platzbecker U, Symeonidis A, Oliva E, Goede J, Delforge M, Mayer J . A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017; 31(9):1944-1950. PMC: 5596208. DOI: 10.1038/leu.2017.192. View

Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G . Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2014; 168(3):361-70. DOI: 10.1111/bjh.13138. View

Platzbecker U, Hofbauer L, Ehninger G, Holig K . The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012; 36(5):525-36. DOI: 10.1016/j.leukres.2012.01.006. View

Oliva E, Finelli C, Santini V, Poloni A, Liso V, Cilloni D . Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res. 2012; 2(2):136-47. PMC: 3384400. View

10.

Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl I, Dybedal I . A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120(6):1037-46. DOI: 10.1046/j.1365-2141.2003.04153.x. View

11.

Crawford J, Cella D, Cleeland C, Cremieux P, Demetri G, Sarokhan B . Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95(4):888-95. DOI: 10.1002/cncr.10763. View

12.

Stauder R, Yu G, Koinig K, Bagguley T, Fenaux P, Symeonidis A . Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018; 32(6):1380-1392. PMC: 5990524. DOI: 10.1038/s41375-018-0089-x. View

13.

Fenaux P, Santini V, Aloe Spiriti M, Giagounidis A, Schlag R, Radinoff A . A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018; 32(12):2648-2658. PMC: 6286328. DOI: 10.1038/s41375-018-0118-9. View

14.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F . Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer. 2017; 124(6):1251-1259. DOI: 10.1002/cncr.31193. View

15.

Balducci L . Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006; 106(10):2087-94. DOI: 10.1002/cncr.21860. View

16.

Kao J, McMillan A, Greenberg P . International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008; 83(10):765-70. DOI: 10.1002/ajh.21249. View

17.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

18.

Fishbane S, Besarab A . Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007; 2(6):1274-82. DOI: 10.2215/CJN.02380607. View

19.

Jansen A, Essink-Bot M, Beckers E, Hop W, Schipperus M, van Rhenen D . Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003; 121(2):270-4. DOI: 10.1046/j.1365-2141.2003.04272.x. View

20.

Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. DOI: 10.1182/blood-2005-10-4149. View